Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow for the year ending December 31, 2023: USD 867.62 M

Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow is USD 867.62 M for the year ending December 31, 2023, a 923.66% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow for the year ending December 31, 2022 was USD -105.34 M, a -126.20% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow for the year ending December 31, 2021 was USD 401.98 M, a -8.82% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow for the year ending December 31, 2020 was USD 440.85 M, a -5.70% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Free Cash Flow for the year ending December 31, 2019 was USD 467.49 M, a 43.21% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years